Search

CN-121985955-A - Probiotics bacillus subtilis for preventing and treating chronic low-grade inflammation

CN121985955ACN 121985955 ACN121985955 ACN 121985955ACN-121985955-A

Abstract

The present invention relates to a strain of bacillus subtilis, in particular a strain of bacillus subtilis CU1 (CNCM I-2745), or cells obtained by culturing the strain, or a composition comprising the strain or the cells, wherein the composition is preferably a functional food or food supplement for preventing, reducing and/or treating low grade inflammation, in particular in healthy elderly individuals.

Inventors

  • Florian Morey
  • Adeline Krinir
  • Bertrand Rodriguez

Assignees

  • 乐斯福公司

Dates

Publication Date
20260505
Application Date
20241004
Priority Date
20231005

Claims (15)

  1. 1. A bacillus subtilis strain deposited under accession number I-2745 on month 25 of 2001 with CNCM (national microbiological culture collection center, basd institute, paris, region 15, lubo street No. 25, postal code 75724) for use in the prevention and/or treatment of chronic low-grade inflammation in an individual.
  2. 2. Cells obtained by culturing a bacillus subtilis strain deposited with CNCM under accession number I-2745 at 10/25/2001 for use in preventing and/or treating chronic low-grade inflammation in an individual.
  3. 3. The cell according to claim 2, wherein the cell is in sporulated and/or vegetative form, advantageously in sporulated form, preferably in sporulated and freeze-dried form.
  4. 4. A composition comprising a bacillus subtilis strain deposited with CNCM under accession number I-2745 or cells obtained by culturing said strain on month 25 of 2001 for use in the prevention and/or treatment of chronic low grade inflammation in an individual.
  5. 5. The composition according to claim 4, wherein the composition comprises the strain or the cell in an amount of greater than or equal to 1x10 9 CFU, advantageously between 1x10 9 and 1x10 10 CFU, such as 2x10 9 CFU.
  6. 6. The composition according to any one of claims 4 to 5, wherein the composition is in a form suitable for oral administration, advantageously in the form of a capsule, pill, lozenge, tablet, capsule, powder, suspension, solution or granule.
  7. 7. The composition of any one of claims 4 to 6, wherein the composition is a functional food or food supplement.
  8. 8. The strain of claim 1, the cell of any one of claims 2 to 3, or the composition of any one of claims 4 to 7, wherein the individual is an elderly person.
  9. 9. A strain according to claim 1 or 8, a cell according to any one of claims 2 to 3 or 8, or a composition according to any one of claims 4 to 8, wherein the individual is less than 65 years old, advantageously less than 60 years old, preferably less than 55 years old.
  10. 10. A strain according to claim 1 or 8, a cell according to any one of claims 2 to 3 or 8, or a composition according to any one of claims 4 to 8, wherein the individual is at least 60 years old, advantageously at least 65 years old.
  11. 11. The strain of any one of claims 1, 8 to 10, the cell of any one of claims 2 to 3, 8 to 10, or the composition of any one of claims 4 to 10, wherein the individual is healthy.
  12. 12. The strain of any one of claims 1, 8 to 11, the cell of any one of claims 2 to 3, 8 to 11, or the composition of any one of claims 4 to 11, wherein the strain, cell, or composition is administered orally.
  13. 13. The strain of any one of claims 1, 8 to 12, the cell of any one of claims 2 to 3, 8 to 12, or the composition of any one of claims 4 to 12, wherein the strain, cell, or composition is administered daily.
  14. 14. The strain of any one of claims 1, 8 to 13, the cell of any one of claims 2 to 3, 8 to 13, or the composition of any one of claims 4 to 13, wherein the strain, cell, or composition is administered for at least 2 weeks.
  15. 15. The strain of claim 14, the cell of claim 14, or the composition of claim 14, wherein the strain, cell, or composition is administered uninterrupted for at least 4 weeks.

Description

Probiotics bacillus subtilis for preventing and treating chronic low-grade inflammation Technical Field The present invention relates to the field of immunization, and in particular to the prevention, reduction and/or treatment of low grade inflammation, especially in elderly people, by specific probiotic strains of bacillus subtilis being administered in the form of functional foods or food supplements. Background The so-called low-grade inflammation is a condition characterized by "low noise" chronic systemic inflammation, without major clinical symptoms, resulting in a general inflammatory background. Characterized by the expression of high levels of inflammatory factors, in particular circulating cytokines, in the affected tissues without any impairment or loss of their primary function (L Ó PEZ-OT Í N Carlos et al (2023) Cell 186 (2), p. 243-278). The causes of low-grade inflammation occur in a variety of ways and are sometimes difficult to determine, but the main causes identified are as follows: -there are a plurality of unknown small infection lesions; -obesity, overweight, metabolic syndrome and insulin resistance; intestinal disorders, dysbacteriosis (dysbiose) and intestinal hyperpermeability; Lifestyle of sedentary, alcoholism, stress, smoking and western-style diet (sugar, processed products, etc.); Allergy, intolerance, and -Age. Thus, it is recognized that most elderly people suffer from this type of inflammation, which is known as "inflammatory aging (INFLAMMAGING)". Such inflammation has the consequence of promoting and/or exacerbating most current chronic diseases, in particular cardiovascular diseases, metabolic diseases (type II diabetes and obesity), cancer, autoimmune diseases, depression and neurological or neuropsychiatric diseases (alzheimer's disease, parkinson's disease, bipolar disorders, etc.). The current management of this inflammation is based on dietary re-balance and the use of food supplements, particularly probiotic-based food supplements. Different bacillus strains, in particular bacillus subtilis, have been commercialized at present for use as probiotics in humans and animals to improve their health. In particular, the strain of Bacillus subtilis CU1 (or BSCU 1) deposited with CNCM (national center for culture of microorganisms, bass institute, area 15 of Paris, lu's street 25, post code 75724) under accession number I-2745, month 10, 2001, is known to be used as a beneficial probiotic. Document WO2014/091160 describes the use of this strain for the prevention and/or treatment of diarrhea. Document WO2014/207360 describes the use of this strain in the prevention and/or treatment of pathologies of the chronic inflammatory rheumatic type (in particular rheumatoid arthritis). However, it must be noted that the prior art shows that certain probiotic-based oral compositions have no systemic effect, as the intestinal mucosa and its barrier function ensure that these compositions are confined in the intestinal lumen/lumen contents are not absorbed and transferred to the circulatory system. The lack of such systemic effects in prior art compositions may be due to the selection of bacterial strains and/or the concentration administered. The effect of the administration of Bacillus subtilis products has been studied in different animal models (rats, layer chickens, broiler chickens) or conditions (long-term and high-intensity physical training) that mimic acute inflammation, see TANG et al. (2022) Front Microbiol 13, doi: 10.3389/fmicb.2022.1005842. ; ZOU et al. (2022) Animal 16(3), p. 100474; CHEN et al. (2022) Journal of Poultry Science 59(3), pp. 260-271; GADDE et al. (2017) Research in Veterinary Science 114, pp. 236-243: TOWNSEND et al. (2018) Sports 6(3), p. 70. Furthermore, LEFEVRE ET al (2015 Immun. Ageing, doi: 10.1186/s 12979-015-0051-y) has observed the effect of supplementation with Bacillus subtilis CU1 on the immune system of elderly people, no differences in circulating cytokines were observed after a daily administration lasting 10 days followed by an interruption of 18 days for 4 months. It is clearly desirable to find a solution to prevent and/or combat low-grade inflammation. Disclosure of Invention Definition of the definition The following definitions are to be construed in accordance with what is commonly used in the context of the present invention and should be considered unless explicitly stated otherwise. In the context of the present invention, the articles "a" and "an" are used to refer to one or more (e.g., to at least one) of the grammatical object of the article. For example, "an element" means at least one element, i.e., one or more elements. The term "about" or "approximately" when used in reference to a measurable value (e.g., number, duration, and other similar values) must be understood to include measurement uncertainties of + -20% or + -10%, preferably + -5%, more preferably + -1%, and particularly preferably + -0.1% of the specified value. I